JP2010511382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511382A5 JP2010511382A5 JP2009539218A JP2009539218A JP2010511382A5 JP 2010511382 A5 JP2010511382 A5 JP 2010511382A5 JP 2009539218 A JP2009539218 A JP 2009539218A JP 2009539218 A JP2009539218 A JP 2009539218A JP 2010511382 A5 JP2010511382 A5 JP 2010511382A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ack1
- amino acid
- nucleic acid
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091000080 Phosphotransferase Proteins 0.000 claims 30
- 102000020233 phosphotransferase Human genes 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 150000001413 amino acids Chemical class 0.000 claims 29
- 235000001014 amino acid Nutrition 0.000 claims 25
- 229940024606 amino acid Drugs 0.000 claims 25
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims 24
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims 24
- 210000004027 cell Anatomy 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 14
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 14
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 claims 13
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 claims 12
- 102000001253 Protein Kinase Human genes 0.000 claims 11
- 108060006633 protein kinase Proteins 0.000 claims 11
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 10
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 9
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 9
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 claims 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 8
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims 8
- 239000002853 nucleic acid probe Substances 0.000 claims 8
- 101150052413 TNK2 gene Proteins 0.000 claims 5
- 101150098329 Tyro3 gene Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 230000001131 transforming effect Effects 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 229930014626 natural product Natural products 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 102220539799 Fibroblast growth factor receptor 4_V10I_mutation Human genes 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000001850 reproductive effect Effects 0.000 claims 3
- 102220198375 rs1057520036 Human genes 0.000 claims 3
- 102200111635 rs13433937 Human genes 0.000 claims 3
- 102200143304 rs351855 Human genes 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 102200074429 rs104894784 Human genes 0.000 claims 2
- 102220304248 rs1243381790 Human genes 0.000 claims 2
- 102200118192 rs33940204 Human genes 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 210000001842 enterocyte Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000034512 ubiquitination Effects 0.000 claims 1
- 238000010798 ubiquitination Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86817306P | 2006-12-01 | 2006-12-01 | |
| PCT/SG2007/000412 WO2008066498A1 (en) | 2006-12-01 | 2007-12-03 | Cancer-related protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511382A JP2010511382A (ja) | 2010-04-15 |
| JP2010511382A5 true JP2010511382A5 (enExample) | 2011-01-27 |
Family
ID=39468190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539218A Pending JP2010511382A (ja) | 2006-12-01 | 2007-12-03 | 癌関連タンパク質キナーゼ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110008347A1 (enExample) |
| EP (1) | EP2094850B1 (enExample) |
| JP (1) | JP2010511382A (enExample) |
| SG (1) | SG177225A1 (enExample) |
| WO (1) | WO2008066498A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| JP2010515921A (ja) * | 2007-01-11 | 2010-05-13 | ジェネンテック， インコーポレイテッド | 腫瘍と関連している遺伝的変異 |
| KR101561403B1 (ko) | 2007-08-30 | 2015-10-16 | 다이이찌 산쿄 가부시키가이샤 | 항ｅｐｈａ２ 항체 |
| JP2011509079A (ja) * | 2007-12-24 | 2011-03-24 | オックスフォード ビオトヘラペウトイクス エルティーディー． | エフリンａ型受容体１０タンパク質 |
| EP2252373B1 (en) * | 2008-02-05 | 2012-06-13 | Urifer Ltd | Novel fer -like protein, pharmaceutical compositions containing it and method for its use |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2165710A1 (en) * | 2008-09-19 | 2010-03-24 | Institut Curie | Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor |
| EP2169071A1 (en) * | 2008-09-29 | 2010-03-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rodent cancer model for human FGFR4 Arg388 polymorphism |
| PE20120021A1 (es) | 2008-10-10 | 2012-02-10 | Amgen Inc | Mutantes fgf21 |
| JP5439494B2 (ja) * | 2008-10-21 | 2014-03-12 | バイエル ヘルスケア エルエルシー | 肝細胞癌と関連するシグネチャ遺伝子の同定 |
| KR102672712B1 (ko) | 2008-11-12 | 2024-06-07 | 인리젠 | 분리된 신장 세포 및 이의 용도 |
| JP5979877B2 (ja) * | 2009-02-12 | 2016-08-31 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト癌における変異ｒｏｓ発現 |
| AU2010246108B2 (en) * | 2009-05-05 | 2014-10-23 | Amgen Inc. | FGF21 mutants and uses thereof |
| MX2011011815A (es) | 2009-05-05 | 2012-01-27 | Amgen Inc | Mutantes fgf21 y usos de los mismos. |
| EP2336171A1 (en) * | 2009-12-11 | 2011-06-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel targets for the treatment of proliferative diseases |
| EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
| EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
| TWI542690B (zh) | 2010-05-12 | 2016-07-21 | 再生醫學Ｔｘ有限責任公司 | 生物活性腎細胞 |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| WO2012068073A2 (en) | 2010-11-15 | 2012-05-24 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting tnk-1 |
| WO2012075158A1 (en) | 2010-12-01 | 2012-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| KR20140098834A (ko) * | 2011-11-30 | 2014-08-08 | 제넨테크, 인크. | 암에서의 erbb3 돌연변이 |
| US10293035B2 (en) | 2014-03-28 | 2019-05-21 | University Of Washington Through Its Center For Commercialization | Breast and ovarian cancer vaccines |
| US11946934B2 (en) | 2014-09-03 | 2024-04-02 | Wellmarker Bio Co., Ltd. | Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof |
| CN106795567B (zh) * | 2014-10-09 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 在表皮生长因子受体激酶结构域中的突变 |
| CA2987281A1 (en) * | 2015-05-29 | 2016-12-08 | Ignyta, Inc. | Compositions and methods for treating patients with rtk mutant cells |
| WO2017070708A1 (en) | 2015-10-23 | 2017-04-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| SG11201803098VA (en) | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
| JP7000660B2 (ja) | 2016-01-20 | 2022-02-04 | ザ スクリプス リサーチ インスティテュート | Ｒｏｒ１抗体組成物及び関連の方法 |
| US11123372B2 (en) | 2016-07-29 | 2021-09-21 | Prokidney | Bioactive renal cells for the treatment of chronic kidney disease |
| CN106480205A (zh) * | 2016-11-11 | 2017-03-08 | 北京吉因加科技有限公司 | 用于同时检测多种突变类型的序列组合和探针 |
| BR112020000793A2 (pt) | 2017-07-19 | 2020-07-14 | Ignyta, Inc. | composições farmacêuticas e formas de dosagem |
| CA3071212C (en) | 2017-08-07 | 2023-12-12 | Nbe-Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| JP7311498B2 (ja) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
| US12077599B2 (en) * | 2017-11-29 | 2024-09-03 | Seoul National University R&Db Foundation, National Cancer Center | Anti-ROS1 antibody and use thereof |
| WO2019133752A1 (en) * | 2017-12-28 | 2019-07-04 | Development Center For Biotechnology | A method for predicting drug efficacy |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| WO2020179844A1 (ja) * | 2019-03-04 | 2020-09-10 | 公益財団法人東京都医学総合研究所 | Ｔｒｋ断片をコードする核酸構築物、及びその利用 |
| CN110031626A (zh) * | 2019-04-02 | 2019-07-19 | 浙江理工大学 | 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| EP4085055A1 (en) | 2019-12-30 | 2022-11-09 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| EP4297873A1 (en) | 2021-02-26 | 2024-01-03 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| EP4547670A1 (en) | 2022-06-29 | 2025-05-07 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| US20250368666A1 (en) | 2022-06-29 | 2025-12-04 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202535368A (zh) | 2023-12-15 | 2025-09-16 | 美商泰拉生物科學公司 | 吲唑化合物 |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| DE3069468D1 (en) * | 1979-12-19 | 1984-11-22 | Nat Res Dev | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE3611194A1 (de) * | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3920029C2 (de) * | 1988-06-30 | 1999-05-20 | Clariant Finance Bvi Ltd | Farbstoffe zum Färben von Kunststoffen |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| SE517975C2 (sv) | 2000-05-30 | 2002-08-13 | Power Ab C | Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion |
| JP2004533206A (ja) * | 2000-10-11 | 2004-11-04 | アバロン ファーマシューティカルズ | 化学療法のための標的としてのガン関連遺伝子 |
| US20050191618A1 (en) | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| US20030157082A1 (en) * | 2002-01-31 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules |
| JP2006174701A (ja) * | 2003-02-24 | 2006-07-06 | Research Association For Biotechnology | 新規タンパク質およびそれをコードするｄｎａ |
| JP2005198640A (ja) * | 2003-11-25 | 2005-07-28 | Biomarker Science:Kk | 遺伝子発現方法 |
-
2007
- 2007-12-03 JP JP2009539218A patent/JP2010511382A/ja active Pending
- 2007-12-03 EP EP07852282.8A patent/EP2094850B1/en not_active Not-in-force
- 2007-12-03 SG SG2011095569A patent/SG177225A1/en unknown
- 2007-12-03 WO PCT/SG2007/000412 patent/WO2008066498A1/en not_active Ceased
- 2007-12-03 US US12/517,050 patent/US20110008347A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511382A5 (enExample) | ||
| JP6352924B2 (ja) | ダイナミックｂｈ３プロファイリング | |
| JP2011505825A (ja) | Ｔｉａｂｓを検出するための組成物及び方法 | |
| JP2019176878A (ja) | Ｄｎａ−蛋白質複合体の組成物 | |
| KR20080114689A (ko) | 증가된 ｂｃｌ-2에 의한 암의 발견 | |
| JP2012115275A5 (enExample) | ||
| JP2011506941A5 (enExample) | ||
| WO2015184443A1 (en) | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy | |
| WO2014135546A1 (en) | Methods and compositions for the diagnosis of alzheimer's disease | |
| JP2008509673A5 (enExample) | ||
| US20230417742A1 (en) | Improved assays to detect nucleosome modifications using antibody-targeted enzyme digestion | |
| JP2011517937A5 (enExample) | ||
| RU2009127735A (ru) | Определение предрасположенности к раку путем идентификации генотипических комбинаций специфичных вариантов генов cyp1b1, brca2 и снек2 | |
| JP2009539370A5 (enExample) | ||
| CN111480079A (zh) | 疾病蛋白质组蛋白质阵列及其应用 | |
| KR101227434B1 (ko) | 유방암 줄기세포 특이적 마커인 ｃｄ４４ 단백질 표적용 펩타이드 및 이의 이용 | |
| CA2687937C (en) | Novel gpiiia gene | |
| US20140065610A1 (en) | Method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders | |
| WO2006124664A2 (en) | Polymorphic ghsr nucleic acids and uses thereof | |
| KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
| JP2009535033A5 (enExample) | ||
| US10745439B2 (en) | Kinase substrates and methods of use thereof | |
| CN101479391A (zh) | 用于检测cripto-3的组合物及方法 | |
| US20140094384A1 (en) | Stromal antigen 2 (stag2) compositions and methods | |
| US8765919B2 (en) | TOX3 as a biomarker for breast cancer |